It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year

Key Insights

• Voyager Therapeutics' Annual General Meeting to take place on 3rd of June
• Salary of US$652.1k is part of CEO Al Sandrock's total remuneration
• The overall pay is comparable to the industry average
• Voyager Therapeutics' three-year loss to shareholders was 52% while its EPS grew by 13% over the past three years

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Shareholders of Voyager Therapeutics, Inc. (NASDAQ:VYGR) will have been dismayed by the negative share price return over the last three years. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. The AGM coming up on the 3rd of June could be an opportunity for shareholders to bring these concerns to the board's attention. Voting on resolutions such as executive remuneration and other matters could also be a way to influence management. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment.

See our latest analysis for Voyager Therapeutics

How Does Total Compensation For Al Sandrock Compare With Other Companies In The Industry?

Our data indicates that Voyager Therapeutics, Inc. has a market capitalization of US$162m, and total annual CEO compensation was reported as US$3.4m for the year to December 2024. That's just a smallish increase of 6.5% on last year. While we always look at total compensation first, our analysis shows that the salary component is less, at US$652k.

On comparing similar companies from the American Biotechs industry with market caps ranging from US$100m to US$400m, we found that the median CEO total compensation was US$3.3m. From this we gather that Al Sandrock is paid around the median for CEOs in the industry. Moreover, Al Sandrock also holds US$392k worth of Voyager Therapeutics stock directly under their own name.

On an industry level, roughly 22% of total compensation represents salary and 78% is other remuneration. Voyager Therapeutics sets aside a smaller share of compensation for salary, in comparison to the overall industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.

A Look at Voyager Therapeutics, Inc.'s Growth Numbers

Voyager Therapeutics, Inc.'s earnings per share (EPS) grew 13% per year over the last three years. Its revenue is down 44% over the previous year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. While it would be good to see revenue growth, profits matter more in the end. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..

Has Voyager Therapeutics, Inc. Been A Good Investment?

The return of -52% over three years would not have pleased Voyager Therapeutics, Inc. shareholders. So shareholders would probably want the company to be less generous with CEO compensation.

In Summary...

The fact that shareholders are sitting on a loss on the value of their shares in the past few years is certainly disconcerting. The stock's movement is disjointed with the company's earnings growth, which ideally should move in the same direction. Shareholders would probably be keen to find out what are the other factors could be weighing down the stock. These concerns should be addressed at the upcoming AGM, where shareholders can question the board and evaluate if their judgement and decision making is still in line with their expectations.

It is always advisable to analyse CEO pay, along with performing a thorough analysis of the company's key performance areas. We identified 3 warning signs for Voyager Therapeutics (1 is concerning!) that you should be aware of before investing here.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.